Kairos Pharma, LTD. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Kairos Pharma announced interim Phase 2 efficacy data for ENV-105 (carotuximab) combined with apalutamide in metastatic castration-resistant prostate cancer. Median progression-free survival was 17.7 months with combination therapy versus 2 months with apalutamide alone (P=0.0008). The company modified the protocol to enroll earlier-stage patients and targets Phase 2 completion by Q4 2027.
Why this rating
Pivotal interim efficacy readout for lead candidate at $6.9M-market-cap clinical-stage firm. Statistically significant PFS improvement is clinically meaningful; protocol expansion signals confidence. De-risks regulatory pathway materially.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-6.2% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.59 | +10 min · unknown $1.50 ▼ 5.96% | +30 min · unknown $1.56 ▼ 2.19% | +1 hr · unknown $1.62 ▲ 1.57% | +4 hrs · unknown $1.17 ▼ 26.65% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.